NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that its Phase 2b PARADIGM study of PrimeC in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE